Clinical Characteristics of COVID-19 Patients With Digestive Symptoms in Hubei, China: A Descriptive, Cross-Sectional, Multicenter Study

Lei Pan, Mi Mu, Pengcheng Yang, Yu Sun, Runsheng Wang, Junhong Yan, Pibao Li, Baoguang Hu, Jing Wang, Chao Hu, Yuan Jin, Xun Niu, Rongyu Ping, Yingzhen Du, Tianzhi Li, Guogang Xu, Qinyong Hu, Lei Tu, Lei Pan, Mi Mu, Pengcheng Yang, Yu Sun, Runsheng Wang, Junhong Yan, Pibao Li, Baoguang Hu, Jing Wang, Chao Hu, Yuan Jin, Xun Niu, Rongyu Ping, Yingzhen Du, Tianzhi Li, Guogang Xu, Qinyong Hu, Lei Tu

Abstract

Objective: Since the outbreak of Coronavirus Disease 2019 (COVID-19) in December 2019, various digestive symptoms have been frequently reported in patients infected with the virus. In this study, we aimed to further investigate the prevalence and outcomes of COVID-19 patients with digestive symptoms.

Methods: In this descriptive, cross-sectional, multicenter study, we enrolled confirmed patients with COVID-19 who presented to 3 hospitals from January 18, 2020, to February 28, 2020. All patients were confirmed by real-time polymerase chain reaction and were analyzed for clinical characteristics, laboratory data, and treatment. Data were followed up until March 18, 2020.

Results: In the present study, 204 patients with COVID-19 and full laboratory, imaging, and historical data were analyzed. The average age was 52.9 years (SD ± 16), including 107 men and 97 women. Although most patients presented to the hospital with fever or respiratory symptoms, we found that 103 patients (50.5%) reported a digestive symptom, including lack of appetite (81 [78.6%] cases), diarrhea (35 [34%] cases), vomiting (4 [3.9%] cases), and abdominal pain (2 [1.9%] cases). If lack of appetite is excluded from the analysis (because it is less specific for the gastrointestinal tract), there were 38 total cases (18.6%) where patients presented with a gastrointestinal-specific symptom, including diarrhea, vomiting, or abdominal pain. Patients with digestive symptoms had a significantly longer time from onset to admission than patients without digestive symptoms (9.0 days vs 7.3 days). In 6 cases, there were digestive symptoms, but no respiratory symptoms. As the severity of the disease increased, digestive symptoms became more pronounced. Patients with digestive symptoms had higher mean liver enzyme levels, lower monocyte count, longer prothrombin time, and received more antimicrobial treatment than those without digestive symptoms.

Discussion: We found that digestive symptoms are common in patients with COVID-19. Moreover, these patients have a longer time from onset to admission, evidence of longer coagulation, and higher liver enzyme levels. Clinicians should recognize that digestive symptoms, such as diarrhea, are commonly among the presenting features of COVID-19 and that the index of suspicion may need to be raised earlier in at-risk patients presenting with digestive symptoms. However, further large sample studies are needed to confirm these findings.

Figures

Figure 1.
Figure 1.
Patients flowchart.
Figure 2.
Figure 2.
Frequency of COVID-19 patients with or without digestive symptoms.

References

    1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: Challenges for global health governance. JAMA 2020;323:709–10.
    1. Wu Y, Ho W, Huang Y, et al. SARS-CoV-2 is an appropriate name for the new coronavirus. Lancet 2020;395:949–50.
    1. Legido-Quigley H, Asgari N, Teo YY, et al. Are high-performing health systems resilient against the COVID-19 epidemic? Lancet 2020;395:848–50.
    1. Wang P, Anderson N, Pan Y, et al. The SARS-CoV-2 outbreak: Diagnosis, infection prevention, and public perception. Clin Chem 2020. [Epub ahead of print March 10, 2020].
    1. Khot WY, Nadkar MY. The 2019 novel coronavirus outbreak—A global threat. J Assoc Physicians India 2020;68:67–71.
    1. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 2020;323:1061–1069.
    1. Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls: Treasure Island, 2020. [Epub ahead of print March 20, 2020].
    1. Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA 2020. [Epub ahead of print March 03, 2020].
    1. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 2020;395:507–13.
    1. Gao QY, Chen YX, Fang JY. 2019 novel coronavirus infection and gastrointestinal tract. J Dig Dis 2020. [Epub ahead of print February 25, 2020].
    1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
    1. Yao N, Wang SN, Lian JQ, et al. Clinical characteristics and influencing factors of patients with novel coronavirus pneumonia combined with liver injury in Shaanxi region [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2020;28:E003.
    1. Hu LL, Wang WJ, Zhu QJ, et al. Novel coronavirus pneumonia related liver injury: Etiological analysis and treatment strategy [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2020;28:E001.
    1. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir Med 2020. [Epub ahead of print February 24, 2020].
    1. Guan GW, Gao L, Wang JW, et al. Exploring the mechanism of liver enzyme abnormalities in patients with novel coronavirus-infected pneumonia [in Chinese]. Zhonghua Gan Zang Bing Za Zhi 2020;28:E002.
    1. Tang A, Tong ZD, Wang HL, et al. Detection of novel coronavirus by RT-PCR in stool specimen from asymptomatic child, China. Emerg Infect Dis 2020;26. [Epub ahead of print March 09, 2020].
    1. Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis 2020;93:264–7.
    1. Xiao F, Tang M, Zheng X, et al. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 2020. [Epub ahead of print March 03, 2020].
    1. Li M, Wang B, Zhang M, et al. Symbiotic gut microbes modulate human metabolic phenotypes. Proc Natl Acad Sci USA 2008;105:2117–22.
    1. Budden KF, Gellatly SL, Wood DL, et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat Rev Microbiol 2017;15:55–63.
    1. He Y, Wen Q, Yao F, et al. Gut-lung axis: The microbial contributions and clinical implications. Crit Rev Microbiol 2017;43:81–95.
    1. Wu J, Liu J, Zhao X, et al. Clinical characteristics of imported cases of COVID-19 in Jiangsu province: A multicenter descriptive study. Clin Infect Dis 2020. [Epub ahead of print February 29, 2020].

Source: PubMed

3
Abonneren